{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:05:24Z","timestamp":1759482324594},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T00:00:00Z","timestamp":1288569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1016\/j.atherosclerosis.2010.08.068","type":"journal-article","created":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T05:25:36Z","timestamp":1283318736000},"page":"235-240","source":"Crossref","is-referenced-by-count":19,"title":["Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: Randomized comparison of fenofibrate 160mg and niacin 1500mg"],"prefix":"10.1016","volume":"213","author":[{"given":"Jin","family":"Wi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong-Youn","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sungha","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok-Min","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangsoo","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namsik","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won-Heum","family":"Shim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Yun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Hak","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0005","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1001\/archinternmed.2008.599","article-title":"Hypertriglyceridemia and its pharmacologic treatment among US adults","volume":"169","author":"Ford","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0010","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"285","author":"Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0015","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case\u2013control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0020","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.2337\/dc07-0015","article-title":"Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome","volume":"30","author":"Rosenson","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.atherosclerosis.2006.10.017","article-title":"Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients","volume":"195","author":"Franceschini","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0030","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","article-title":"Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia","volume":"85","author":"Goldberg","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0035","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2337\/diacare.25.7.1198","article-title":"Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia","volume":"25","author":"Athyros","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0040","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1016\/j.clinthera.2009.12.007","article-title":"Efficacy and tolerability of atorvastatin\/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study","volume":"31","author":"Davidson","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0045","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0050","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials","volume":"45","author":"Birjmohun","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0055","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1210\/jc.2009-1487","article-title":"Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome","volume":"95","author":"Belfort","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0060","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.amjcard.2008.07.010","article-title":"Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20mg) versus fenofibrate (200mg) versus extended-release niacin (2g)","volume":"102","author":"Alrasadi","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0065","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2796.1989.tb01393.x","article-title":"Pronounced lowering of serum levels of lipoprotein Lp (a) in hyperlipidemic subjects treated with nicotinic acid","volume":"226","author":"Carlson","year":"1989","journal-title":"J Intern Med"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0070","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1210\/jc.2009-2622","article-title":"Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease","volume":"95","author":"Fabbrini","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0075","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jama.284.10.1263","article-title":"Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial","volume":"284","author":"Elam","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0080","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jacc.2006.05.009","article-title":"The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study","volume":"48","author":"Muhlestein","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0085","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1111\/j.1742-1241.2007.01597.x","article-title":"The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome","volume":"61","author":"Theones","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0090","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.amjcard.2006.04.011","article-title":"Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease","volume":"98","author":"Kuvin","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0095","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety consideration with fibrate therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00003495-200767010-00013","article-title":"Fenofibrate: a review of its use in primary dyslipidemia, the metabolic syndrome and type 2 diabetes mellitus","volume":"67","author":"Keating","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0105","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4065\/mcp.2009.0535","article-title":"A \u201chot\u201d topic in dyslipidemia management-\u201cHow to beat a flush\u201d: optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention","volume":"85","author":"Jacobson","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0110","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0115","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0120","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2174\/138955710791185046","article-title":"Niacin: from mechanisms of action to therapeutic uses","volume":"10","author":"Al-Mohaissen","year":"2010","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.atherosclerosis.2010.08.068_bib0130","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2010.01.008","article-title":"Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk","volume":"126","author":"Chapman","year":"2010","journal-title":"Pharmacol Ther."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915010007161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915010007161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T07:58:42Z","timestamp":1544255922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915010007161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,11]]}},"alternative-id":["S0021915010007161"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2010.08.068","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}